YOLFTbeta
Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd

KNSA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

96.33USD+0.05 (+0.05%)

Price History

Full chart

Market Stats

Previous Close96.28
Open96.37
Day Range94.51 – 96.75
52-Week Range36.56 – 90.80
Volume464.98K
Market Cap5.69B
P/E (TTM)73.72
Forward P/E59.88
EPS0.99
Dividend Yield0.00%
Beta0.04
50-Day Avg78.03
200-Day Avg59.14

About

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Sanjiv K. Patel
  • Employees366
  • Headquarters105 Piccadilly, London, United Kingdom, W1J 7NJ, USA
  • Websitehttps://www.kiniksa.com

Leadership

  • Mr. Sanjiv K. PatelCEO & Chairman of the Board · b. 1969
  • Dr. John F. Paolini FACC, M.D., Ph.D.Executive VP & Chief Medical Officer · b. 1965
  • Mr. Eben TessariConsultant · b. 1982
  • Mr. Michael R. Megna CPASenior VP & Chief Accounting Officer · b. 1971
  • Ms. Mei JangSenior VP & Chief Technical Officer
  • Mr. Jonathan KirshenbaumInvestor Relations Officer
  • Mr. Douglas J. BarrySenior VP, Chief Legal Officer & Secretary
  • Ms. Martina Struck Ph.D.Senior VP & Chief Regulatory Officer
  • Mr. Joseph PirrelloChief Business Officer
  • Mr. Aaron YoungChief Intellectual Property Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00007.70M38.54M220.18M270.26M423.24M677.56M
Growth (%)-----+400.31%+471.24%+22.74%+56.60%+60.09%
Cost of Revenue22.00K28.00K286.00K3.28M3.81M9.10M22.89M56.52M60.91M307.41M
Gross Profit-22.00K-28.00K-286.00K-3.28M-3.81M29.44M197.28M213.74M362.33M370.15M
Gross Margin-----49.39%76.39%89.60%79.09%85.61%54.63%
Operating Expense23.98M65.37M107.87M166.68M153.56M186.08M187.51M238.93M407.94M292.93M
Operating Income-24.00M-65.40M-108.16M-169.96M-157.36M-156.64M9.77M-25.20M-45.62M77.22M
Operating Margin-----2042.61%-406.38%4.44%-9.32%-10.78%11.40%
EBITDA-23.98M-65.37M-107.87M-167.90M-154.96M-154.28M13.43M-14.31M-34.46M90.42M
EBITDA Margin-----2011.40%-400.27%6.10%-5.30%-8.14%13.35%
Net Income-23.97M-64.87M-103.23M-161.87M-161.38M-157.92M183.36M14.08M-43.19M59.01M
Net Income Margin-----2094.77%-409.72%83.28%5.21%-10.21%8.71%
R&D17.44M56.36M86.60M135.00M112.04M99.30M65.49M76.10M111.62M96.85M
R&D as % of Total Revenue----1454.34%257.62%29.74%28.16%26.37%14.29%
Interest Expense0008.12M3.54M2.45M1.25M---
Interest Expense % of Total Revenue----45.94%6.36%0.57%---

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets56.47M47.49M321.96M254.53M349.46M232.80M459.67M526.32M580.55M763.63M
Total Liabilities82.20M137.20M42.70M29.11M37.53M47.76M63.52M87.48M142.12M196.03M
Total Equity-25.73M-89.71M-194.22M225.42M311.94M185.04M396.15M438.84M438.44M567.61M
Cash55.97M45.55M307.30M46.93M114.04M122.47M122.72M107.95M183.58M165.60M
Total Debt---2.65M6.99M6.05M5.92M12.26M9.86M9.50M
Net Debt-55.97M-45.55M-307.30M-44.28M-107.05M-116.42M-116.80M-95.70M-173.73M-156.10M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-21.87M-50.22M-81.01M-158.37M-136.53M-126.30M5.81M13.30M25.69M25.69M
Investing Cash Flow-3.00K-69.00K-239.20M49.21M-23.44M128.63M-8.08M-29.56M37.67M37.67M
Financing Cash Flow42.51M39.87M346.74M84.11M227.09M5.88M2.52M1.50M12.27M12.27M
Capital Expenditure3.00K69.00K5.29M3.20M283.00K20.41M105.00K130.00K277.00K277.00K
Free Cash Flow-21.87M-50.29M-86.30M-161.57M-136.81M-146.71M5.70M13.17M25.41M25.41M
FCF to OCF100.01%100.14%106.53%102.02%100.21%116.16%98.19%99.02%98.92%98.92%

Earnings

Report DateMar 7, 2018May 24, 2018Aug 6, 2018Nov 1, 2018Mar 7, 2019May 2, 2019Aug 12, 2019Oct 28, 2019Feb 26, 2020Apr 28, 2020Jul 30, 2020Nov 5, 2020Feb 23, 2021May 4, 2021Aug 3, 2021Nov 1, 2021Feb 22, 2022May 3, 2022Aug 3, 2022Nov 1, 2022Feb 28, 2023May 2, 2023Jul 25, 2023Oct 31, 2023Feb 28, 2024Apr 23, 2024Jul 23, 2024Oct 29, 2024Feb 25, 2025Apr 29, 2025Jul 29, 2025Oct 28, 2025Feb 24, 2026Apr 28, 2026Jul 28, 2026Oct 27, 2026
EPS Estimate0.00--0.50-0.53-0.75-0.79-0.76-0.70-0.62-0.62-0.58-0.59-0.62-0.63-0.77-0.63-0.42-0.26-0.390.83-0.14-0.21-0.13-0.16-0.14-0.080.010.070.020.280.260.370.400.160.300.31
EPS Actual0.02-0.10-0.47-0.51-0.88-0.73-0.68-0.49-0.58-0.48-0.65-0.66-0.79-0.72-0.61-0.44-0.53-0.36-0.293.180.06-0.180.21-0.200.35-0.25-0.06-0.18-0.120.110.230.230.170.270.300.56
Surprise--6.00%3.77%-17.33%7.59%10.53%30.00%6.45%22.58%-12.07%-11.86%-27.42%-14.29%20.78%30.16%-26.19%-38.46%25.64%283.13%142.86%14.29%261.54%-25.00%350.00%-212.50%-700.00%-357.14%-700.00%-60.71%-11.54%-37.84%-57.50%68.75%0.00%80.65%
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap5.69B
Enterprise Value5.47B
Trailing P/E73.72
Forward P/E59.88
Price / Sales6.77
Price / Book9.15
EPS0.99
Book Value8.39
Revenue (TTM)840.85M
Gross Profit (TTM)458.30M
EBITDA102.04M
Profit Margin9.59%
Operating Margin11.16%
Return on Equity14.04%
Return on Assets8.05%
Shares Outstanding48.29M
Shares Float39.86M
Beta0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 98.00
  • Strong Buy
    7
  • Buy
    1

Ownership Breakdown

Institutions
101.82%
Insiders
3.51%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    6.97M8.93%
  • Rubric Capital Management LP
    4.00M5.13%
  • Baker Bros Advisors LP
    2.83M3.63%
  • BlackRock Inc
    2.74M3.51%
  • TANG CAPITAL MANAGEMENT LLC
    2.26M2.90%
  • Vanguard Portfolio Management, LLC
    1.91M2.45%
  • Vanguard Capital Management, LLC
    1.36M1.74%
  • Morgan Stanley - Brokerage Accounts
    1.01M1.30%
  • Arrowstreet Capital Limited Partnership
    957.51K1.23%
  • Spruce Street Capital LP
    918.07K1.18%
  • Dimensional Fund Advisors, Inc.
    874.79K1.12%
  • Amvescap Plc.
    772.81K0.99%
  • Driehaus Capital Management LLC
    718.20K0.92%
  • State Street Corp
    704.19K0.90%
  • Acadian Asset Management LLC
    679.08K0.87%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.39M1.78%
  • iShares Russell 2000 ETF
    1.18M1.51%
  • Vanguard Small Cap Index
    978.74K1.25%
  • Fidelity Select Health Care
    970.00K1.24%
  • Strategic Advisers Fidelity US TtlStk
    676.15K0.87%